
Aurélien Lebreton

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3185264/publications.pdf Version: 2024-02-01



ALIDÃOLIEN LEBDETON

e

#	Article	IF	CITATIONS
1	Natural history of patients with congenital dysfibrinogenemia. Blood, 2015, 125, 553-561.	1.4	138
2	Increased factor VIII plays a significant role in plasma hypercoagulability phenotype of patients with cirrhosis. Journal of Thrombosis and Haemostasis, 2018, 16, 1132-1140.	3.8	58
3	Hypotheses behind the very rare cases of thrombosis with thrombocytopenia syndrome after SARS-CoV-2 vaccination. Thrombosis Research, 2021, 203, 163-171.	1.7	52
4	Prospective evaluation of a rapid nanoparticle-based lateral flow immunoassay (STic) Tj ETQq0 0 0 rgBT /Overlock Haematology, 2014, 166, 774-782.	10 Tf 50 2.5	627 Td (Exp 41
5	Thrombin Generation and Cirrhosis: State of the Art and Perspectives. Seminars in Thrombosis and Hemostasis, 2020, 46, 693-703.	2.7	33
6	Comparative Analysis of a French Prospective Series of 144 Patients with Heparin-Induced Thrombocytopenia (FRIGTIH) and the Literature. Thrombosis and Haemostasis, 2020, 120, 1096-1107.	3.4	29
7	Prevalence and epitope specificity of non-neutralising antibodies in a large cohort of haemophilia A patients without inhibitors. Thrombosis and Haemostasis, 2011, 105, 954-961.	3.4	28
8	Plasma hypercoagulability in the presence of thrombomodulin but not of activated protein C in patients with cirrhosis. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 916-924.	2.8	24
9	Epicatechin influences primary hemostasis, coagulation and fibrinolysis. Food and Function, 2019, 10, 7291-7298.	4.6	24
10	Hypercoagulability (thrombin generation) in patients with cirrhosis is detected with STâ€Genesia. Journal of Thrombosis and Haemostasis, 2020, 18, 2177-2190.	3.8	23
11	Microparticle phenotypes are associated with driver mutations and distinct thrombotic risks in essential thrombocythemia. Haematologica, 2016, 101, e365-e368.	3.5	22
12	Successful pregnancy under fibrinogen substitution in a woman with congenital afibrinogenaemia complicated by a postpartum venous thrombosis. Haemophilia, 2015, 21, e108-10.	2.1	19
13	Discontinuous epitopes on the C2 domain of coagulation Factor VIII mapped by computerâ€designed synthetic peptides. British Journal of Haematology, 2011, 155, 487-497.	2.5	16
14	Diagnosis of congenital fibrinogen disorders. Annales De Biologie Clinique, 2016, 74, 405-412.	0.1	15
15	Long-Term Antithrombotic Treatments Prescribed for Cardiovascular Diseases in Patients with Hemophilia: Results from the French Registry. Thrombosis and Haemostasis, 2021, 121, 287-296.	3.4	14
16	Dabigatran Level Before Reversal Can Predict Hemostatic Effectiveness of Idarucizumab in a Real-World Setting. Frontiers in Medicine, 2020, 7, 599626.	2.6	11
17	PEPOP 2.0: new approaches to mimic non-continuous epitopes. BMC Bioinformatics, 2019, 20, 387.	2.6	10
18	Favorable Outcome of Rivaroxaban-Associated Intracerebral Hemorrhage Reversed by 4-Factor Prothrombin Complex Concentrate. A & A Case Reports, 2015, 4, 151-154.	0.7	9

#	Article	IF	CITATIONS
19	Computerâ€predicted peptides that mimic discontinuous epitopes on the A2 domain of factor VIII. Haemophilia, 2015, 21, e193-201.	2.1	9
20	Determinants of adherence and consequences of the transition from adolescence to adulthood among young people with severe haemophilia (TRANSHEMO): study protocol for a multicentric French national observational cross-sectional study. BMJ Open, 2018, 8, e022409.	1.9	9
21	Low Molecular Weight Heparin Induced Skin Necrosis without Platelet Fall Revealing Immunoallergic Heparin Induced Thrombocytopenia. Case Reports in Hematology, 2013, 2013, 1-3.	0.4	8
22	Are low-density lipoprotein receptor-related protein 1 or non-neutralizing antibodies predictors of FVIIIin vivorecovery in haemophilia A patients?. Haemophilia, 2014, 20, e406-e408.	2.1	6
23	In vitro assessment of edoxaban anticoagulant effect in pediatric plasma. Thrombosis Research, 2019, 178, 112-118.	1.7	6
24	Impact of Epicatechin on the Procoagulant Activities of Microparticles. Nutrients, 2020, 12, 2935.	4.1	6
25	Impact of epicatechin on fibrin clot structure. European Journal of Pharmacology, 2021, 893, 173830.	3.5	6
26	Interlaboratory variability of activated protein C resistance using the ETPâ€based APC resistance assay. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12612.	2.3	6
27	Characteristics and outcomes of reversed patients admitted to an emergency department for VKA-related intramuscular hematoma. American Journal of Emergency Medicine, 2018, 36, 1257-1261.	1.6	5
28	Gastrointestinal bleeding from angiodysplasia in von Willebrand disease: Improved diagnosis and outcome prediction using videocapsule on top of conventional endoscopy. Journal of Thrombosis and Haemostasis, 2021, 19, 380-386.	3.8	5
29	Severe undernutrition increases bleeding risk on vitamin-K antagonists. Clinical Nutrition, 2021, 40, 2237-2243.	5.0	4
30	Prospective Evaluation of a Rapid Nanoparticle-Based Lateral Flow Immunoassay (Stic Expert HIT®) for the Diagnosis of Heparin-Induced Thrombocytopenia. Blood, 2012, 120, 1087-1087.	1.4	4
31	Stability of coagulation parameters in plasma samples at room temperature after one freeze/thaw cycle. International Journal of Laboratory Hematology, 2022, 44, 610-618.	1.3	4
32	Analytical performance of a new immunoturbidimetric Dâ€dimer assay and comparison with available assays. Research and Practice in Thrombosis and Haemostasis, 2022, 6, e12660.	2.3	4
33	Les anticorps anti-FVIII et anti-FIX. Revue Francophone Des Laboratoires, 2012, 2012, 55-62.	0.0	3
34	Repeated early hemofiltration filters clotting and heparin-induced thrombocytopenia in ICU. Journal of Clinical Monitoring and Computing, 2015, 29, 25-28.	1.6	3
35	Measurements of eftrenonacog alfa by 19 different combinations reagents/instrument: A singleâ€centre study. Haemophilia, 2020, 26, 543-552.	2.1	3
36	Are all heparins safe for on-pump heart surgery?. Expert Opinion on Drug Safety, 2016, 15, 897-901.	2.4	2

Aurélien Lebreton

#	Article	IF	CITATIONS
37	Evaluation of a rapid centrifugation step (4500 <i>g</i> for 2 min) in coagulation assays to monitor direct oral anticoagulants. Clinical Chemistry and Laboratory Medicine, 2018, 57, e37-e40.	2.3	2
38	The centrifuge brake impacts neither routine coagulation assays nor platelet count in platelet-poor plasma. Clinical Chemistry and Laboratory Medicine, 2020, 58, e185-e188.	2.3	2
39	Low sensitivity to thrombomodulin in patients with cirrhosis; Impact of factor VIII increase and protein C deficiency. Journal of Hepatology, 2017, 66, S143-S144.	3.7	1
40	Impact of pneumatic tube system transport for the monitoring of heparin therapy. Thrombosis Research, 2017, 158, 35-37.	1.7	1
41	After the <scp>SIPPET</scp> study: Position paper of the Co <scp>METH</scp> , the French society of haemophilia. Haemophilia, 2018, 24, e55-e57.	2.1	1
42	Extrahepatic portal vein obstruction (EHPVO) in cirrhosis. Clinics and Research in Hepatology and Gastroenterology, 2020, 44, 497-502.	1.5	1
43	Epicatechin Impact on Primary Hemostasis, Coagulation and Fibrinolysis. Blood, 2015, 126, 4677-4677.	1.4	1
44	Hemizygous <i>FGG</i> p.Ala108Gly in a hypofibrinogenemic patient with a heterozygous 14.8 Mb deletion encompassing the entire fibrinogen gene cluster. Haemophilia, 2022, 28, .	2.1	1
45	Dosage de l'homocystéine plasmatique, comparaison de deux méthodesÂ: CLHP versus immunonéphélémétrie. Immuno-Analyse Et Biologie Specialisee, 2009, 24, 155-159.	0.0	0
46	Hémostase et cirrhose. Revue Francophone Des Laboratoires, 2014, 2014, 65-72.	0.0	0
47	Cirrhose et hémostase. Revue Francophone Des Laboratoires, 2017, 2017, 56-63.	0.0	0
48	Study of thrombin generation in three populations of patients on oral anticoagulants: Bleeding with reversion, haemorrhagic accidents without reversion or haemorrhagic accident. Archives of Cardiovascular Diseases Supplements, 2020, 12, 190-191.	0.0	0
49	Prevalence and Epitope Specificity of Non-Neutralizing Antibodies in Haemophilia A Patients without Inhibitors Using a Multiplex x-MAP Technology Blood, 2009, 114, 3493-3493.	1.4	0
50	Stability Of Thrombin Generation In Cirrhotic Patients. Blood, 2013, 122, 2361-2361.	1.4	0
51	Resistance to Thrombomodulin but Not to Activated Protein C in Cirrhotic Patients. Blood, 2014, 124, 2839-2839.	1.4	0
52	Global fibrinolytic profile in patients with chronic thromboembolic pulmonary hypertension. , 2015, , .		0
53	Soluble Endothelial Protein C Receptor (sEPCR) Is Increased in Cirrhotic Patients. A Possible Role in Procoagulant Imbalance?. Blood, 2015, 126, 1080-1080.	1.4	0
54	Hypercoagulability in Cirrhotic Patients; Impact of Acquired Protein C Deficiency and Factor VIII Increase in Low Sensitivity to Thrombomodulin. Blood, 2016, 128, 1420-1420.	1.4	0

#	ARTICLE	IF	CITATIONS
55	The Management of Cardiovascular Diseases in Patients with Hemophilia: The French Coche Registry. Blood, 2018, 132, 5018-5018.	1.4	0
56	Measuring rFIX-Fc with 17 Different Combinations Coagulometers — Reagents: A Single Center Study. Blood, 2018, 132, 5016-5016.	1.4	0